Catherine Scott-Wilson

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial

Fernando J. Martínez, Joseph Boscia, Gregory Feldman et al. · Respiratory Medicine · 2013 · 140 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD

Edward Kerwin, Catherine Scott-Wilson, Lisa Sanford et al. · Respiratory Medicine · 2013 · 117 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD

Surya P. Bhatt, Mark Dransfield, John Cockcroft et al. · International Journal of COPD · 2017 · 54 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

Henry D. Covelli, Bonavuth Pek, Isabelle Schenkenberger et al. · International Journal of COPD · 2015 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

Thomas M. Siler, Atsushi Nagai, Catherine Scott-Wilson et al. · Respiratory Medicine · 2016 · 53 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17